A Study of GR1802 in Participants With Chronic Sinusitis With Nasal Polyps

Exclusion Criteria

• •Biologic therapy within 5 half-lives or within 10 weeks before baseline.
• •Anti-IL-4Rα antibody before screening.
• •An experimental drug within 5 half-lives or 1 months before baseline.
• •Systemic immunosuppressant to treat inflammatory disease or autoimmune disease within 2 months or 5 half-lives before baseline.
• •Initiation of allergen immunotherapy within 3 months before screening.
• •Participants receiving leukotriene antagonist/modifier before screening unless on continous treatment for at least 30 days.
• •Participants with FEV1 50% or less of predicted normal were excluded.
• •Participants who have undergone any intranasal and/or sinus surgery within 6 months before screening.
• •Acute sinusitis or upper respiratory infection within a defined time period before screening.
• •A nasal cavity tumor (malignant or benign).
• •Evidence of fungal rhinosinusitis.
• •Presence of another diagnosis associated with nasal polyps (i.e., eosinophilic granulomatosis with polyangiitis, granulomatosis with polyangiitis, Young's syndrome, cystic fibrosis).
• •Rhinitis medicamentosa.
• •Nasal septal deviation occluding at least one nostril.
• •Antrochoanal polyps.
• •Pregnant or lactating woman.